|
| |
| |
|
 |
BAC AND GE HEALTHCARE ANNOUNCE
FVIII PURIFICATION MEDIA COLLABORATION
|
Naarden, The Netherlands, 2nd April 2007 – BAC BV, the Bio Affinity
Company announced today that it has entered into a collaboration with GE
Healthcare, a unit of General Electric Company (NYSE: GE), to develop and market
affinity chromatography media for the purification of therapeutic recombinant
FVIII. BAC will provide its CaptureSelect® affinity ligands, renowned for their
high stability and specificity, to enable efficient process-scale purification
of FVIII for the prevention and treatment of bleeding in patients with
Haemophilia A.
CaptureSelect® ligands exploit the nature of Camelid single chain antibody
fragments and offer enhanced stability and broad antigen-specific binding
compared to traditional affinity ligands. These affinity ligands are
manufactured using a high-yielding proprietary yeast-based expression system,
which is completely animal-free. BAC can rapidly discover and develop
CaptureSelect® ligands for chromatographic separations that can be customised
for use in the manufacture of a range of biopharmaceuticals, including
recombinant proteins, antibodies, antibody fragments and viruses.
“We are extremely pleased that GE Healthcare wishes to further develop and
distribute our recombinant FVIII purification ligand products,” commented
Laurens Sierkstra, CEO of BAC “This agreement endorses our technology and
extends its accessibility to GE’s customers worldwide.”
ABOUT BAC
BAC BV – The Bio Affinity Company – offers a wide range of products and
services for affinity purification of biological materials from complex media.
The Company’s proprietary CaptureSelect® affinity ligands, based on Camelid
single chain antibody fragments, have been proven to be suitable in a wide range
of biological applications including Life Science Research, Biomanufacturing and
Healthcare.
CaptureSelect® ligand technology is based on selection of single chain antibody
fragments with desirable chromatographic characteristics including robustness,
high specificity and flexibility. Suitable ligands are cloned and expressed in
high-titers through an animal-free Saccharomyces cerevisiae-based process that
delivers a highly competitive cost of goods.
BAC BV was established in 1995 as a Unilever subsidiary. Currently the Company
employs 28 people with an R&D laboratory facility in Vlaardingen and a
state-of-the-art ISO 9001 certified manufacturing plant in Naarden, the
Netherlands. For more information about BAC, visit our website at
www.bac.nl. For more information about
CaptureSelect® products, visit our website at
www.captureselect.com
Media Enquiries to:
Ben Routley, Northbank Communications
Email: b.routley@northbankcommunications.com
Tel: +44 (0)1260 296508
Kathryn Robertson, Northbank Communications
Email: Kj.robertson@northbankcommunications.com
Tel: +44 (0)1260 296506 | |
|
